Renal bypass surgery is a minimally invasive surgical method to treat chronic hypertension. Patients who have congestive heart failure are candidates for this procedure, which improves blood flow in the body by bypassing the organ. A balloon catheter is inflated to increase blood flow in the body's extremities such as legs and feet. This balloon catheter is attached to a thin tube that empties it into the abdominal cavity. As far as the regional footprint is considered, Europe seems to be gaining robust traction in the renal denervation devices market. This is typically due to the fact there is an increasing prevalence of cardiovascular diseases in the region. On the contrary, Europe seems to exhibit promising signs with rising occurrence of diabetes in emerging economies.
The typical application of renal denervation devices is in the treatment of resistant hypertension. Over the years, hypertension has become one of the most significant lifestyle diseases, which could lead to various other health-related complications. As per the Centers for Disease Control and Prevention (CDC), in the U.S., in 2020, around 108 million people have hypertension, which is defined as systolic blood pressure. Furthermore, according to the American Institute of Stress, in 2020, around 33% of people report extreme stress in the U.S. Such a high incidence of hypertension and stress is necessitating adequate treatment options. Hence, such factors can stimulate growth of the renal denervation devices market.
That being said, there are certain factors that can pose a major challenge to the growth of the market. For instance, renal denervation procedure is highly painful, and thus many patients tend to opt for minimally invasive surgical procedures. Besides, stringent regulations on product approvals and reimbursement systems can potentially impede growth of the renal denervation devices market in the near future.
One of the major advantages of renal denervation devices is that these devices offer long-lasting effects as compared to other surgical procedures. Besides, over the years, these devices have improved significantly due to technological advancements and continuous research and development activities by key medical device manufacturers. Therefore, these factors can potentially augment growth of the renal denervation devices market in the near future. Recently, in March 2020, Medtronic plc announced the first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial, which showed superiority for renal denervation in patients with high blood pressure as compared to the Sham procedure.
Read More @ https://digitalinsightscmi-blog.blogspot.com/2021/07/with-medtronic-plc-announcing-first.html
